Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Ibuprofen Lozenge in Acute Sore Throat Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01785862
Recruitment Status : Completed
First Posted : February 7, 2013
Last Update Posted : June 27, 2013
Information provided by (Responsible Party):
Pierre Fabre Medicament

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of repeated doses of a low dosage of oromucosal Ibuprofen form (lozenge) versus placebo in patients suffering from acute sore throat pain.

Condition or disease Intervention/treatment Phase
Acute Sore Throat Pain Drug: Ibuprofen 25 mg Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 427 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study of Efficacy and Safety of V0498 Versus Placebo in Acute Sore Throat Pain.
Study Start Date : February 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sore Throat

Arm Intervention/treatment
Experimental: Drug
V0498, Ibuprofen 25 mg
Drug: Ibuprofen 25 mg
Lozenge, Oromucosal administration

Placebo Comparator: Placebo
Drug: Placebo
Lozenge matching V0498 lozenge, Oromucosal administration

Primary Outcome Measures :
  1. Total Pain relief over 2 hours [ Time Frame: 0-2 hours post-dose ]
    Total Pain Relief (TOTPAR) assessed on a 7-point rating scale called the Sore Throat Relief Scale (STRS) over 120min after the start of sucking of 1st study drug administered

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • male or female aged at least 18 years old
  • patient with an acute sore throat

Exclusion Criteria:

  • Severe respiratory tract infection (pneumonia, bronchitis or laryngitis)
  • Oro-pharyngeal paresthesia or mycosis
  • Severely traumatised and/or very severe oromucosal inflammation
  • Tonsillopharyngectomy
  • Peritonsillar abscess
  • Hypersensitivity to ibuprofen or other NonSteroidal Anti-Inflammatory Drugs (NSAIDs) (including bronchospasm) or to excipients
  • Long term use (≥ 3 times per week within the last month or regular intake within the last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow release analgesic intake including NonSteroidal Anti-Inflammatory Drugs (NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)
  • Any anti-inflammatory drugs intake by systemic route within 12 hours before randomisation
  • Any paracetamol intake within 6 hours before randomisation
  • Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6 hours before randomisation
  • Any topical throat medication intake containing or not a local oral anaesthetic such as lozenge, spray, mouth rinse within 4 hours before randomisation
  • Heavy smokers (>20 cigarettes/day)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01785862

Layout table for location information
Gières, France
Erfurt, Germany
Balvi, Latvia
Daugavpils, Latvia
Jekabpils, Latvia
Jelgava, Latvia
Kuldiga, Latvia
Liepaja, Latvia
Ogres Municipality, Latvia
Ogre, Latvia
Riga, Latvia
Saldus, Latvia
United Kingdom
Cardiff, United Kingdom
Glasgow, United Kingdom
Sponsors and Collaborators
Pierre Fabre Medicament

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Pierre Fabre Medicament Identifier: NCT01785862    
Other Study ID Numbers: V00498 TA 3 01
2012-004423-20 ( EudraCT Number )
First Posted: February 7, 2013    Key Record Dates
Last Update Posted: June 27, 2013
Last Verified: June 2013
Keywords provided by Pierre Fabre Medicament:
sore throat pain
upper respiratory tract infection
Additional relevant MeSH terms:
Layout table for MeSH terms
Pharyngeal Diseases
Stomatognathic Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action